Erwin Roggen took a degree in Biochemistry at the University of Antwerp (1984). Over time, he expanded his scientific expertise into the areas of protein chemistry, molecular biology, immunology and cell biology, and he acquired management skills as Project Manager of an international research project funded by the Swedish Agency for Research aiming at understanding better the interaction between HIV and other sexually transmitted diseases.
As science manager for In Vitro (Immuno)Toxicology, coordinator of the FP6 funded project Sens-it-iv, and board member of the Carcinogenomics project, Dr. Roggen acquired extensive expertise in the fields of in vitro/in silico immunology, (immuno-)toxicology, and risk assessment and management.
Throughout the years, Dr. Roggen has actively pursued the development, implementation and acceptance by regulatory bodies of the 3Rs (Refinement, Reduction and Replacement of Animal Experimentation) as chairman of the task force on respiratory sensitisation and member of the task force on skin sensitisation (ECVAM), as member of the ECVAM Scientific Advisory Board (ESAC), co-chair of the EPAA Platform on 3Rs in Regulation, active member of the EPAA Platforms on Science, and Communication and Dissemination, president of IVTIP, and as board member of the Dutch Center for Toxicogenomics and the Dutch 'Assuring Safety without Animal Testingi initiative. He is also member of the editorial board of Toxicology In Vitro and Frontiers in Pharmacology (In Vitro Toxicology), and invited reviewer for Toxicological Sciences, among others.
Dr. Erwin L. Roggen
Novozymes A/S
Krogshoejvej 36
DK-2880 Bagsvaerd
Denmark
Email: elro@novozymes.com
|
